Mechanisms of Resistance to Egfr-Targeted Therapies in Colorectal Cancer: More Than Just Genetics

Authors

Christine Parseghian
Madhulika Eluri
Scott Kopetz
Kanwal Raghav

Publication Date

1-1-2023

Journal

Frontiers in Cell Development Biology

DOI

10.3389/fcell.2023.1176657

PMID

37791069

PMCID

PMC10542118

PubMedCentral® Posted Date

9-15-2023

PubMedCentral® Full Text Version

Post-print

Abstract

The development of acquired resistance to anti-EGFR therapies remains poorly understood, with most research to date exploring, and trying to overcome, various genomic mechanisms of resistance. However, recent work supports a model of resistance whereby transcriptomic mechanisms of resistance predominate in the presence of active cytotoxic chemotherapy combined with anti-EGFR therapy in the first-line setting, with a greater predominance of acquired MAPK mutations after single-agent anti-EGFR therapy in the later-line setting. The proposed model has implications for prospective studies evaluating anti-EGFR rechallenge strategies guided by acquired MAPK mutations and highlights the need to address transcriptional mechanisms of resistance.

Keywords

anti-EGFR, anti-EGFR rechallenge, anti-EGFR resistance, genomic mechanisms of resistance to anti-EGFR, non-genomic mechanisms of resistance to anti-EGFR, anti-EGFR, anti-EGFR rechallenge, genomic mechanisms of resistance to anti-EGFR, non-genomic mechanisms of resistance to anti-EGFR, anti-EGFR resistance

Published Open-Access

yes

Recommended Citation

Parseghian, Christine; Eluri, Madhulika; Kopetz, Scott; et al., "Mechanisms of Resistance to Egfr-Targeted Therapies in Colorectal Cancer: More Than Just Genetics" (2023). Faculty, Staff and Student Publications. 4610.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/4610